Eli Lilly (NYSE:LLY) today announced deals with four companies whose diabetes management tech will work with Lilly’s latest insulin pen. The Tempo Pen is a modified version of Lilly’s existing prefilled, disposable insulin pen to which the Tempo Smart Button — in late-stage development – attaches. Through these new agreements, the Tempo Smart Button will […]
Dexcom
MedTech 100 roundup: Return to normal following recent spike
After back-to-back all-time best performances, the medtech industry had a slight regression over the course of the last week. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — had been continuously ticking up since the beginning of April, with its mark of 112.25 on April 16 representing an all-time […]
Dexcom dips after hours despite Street-beating Q1, raised guidance
Dexcom (NSDQ:DXCM) shares took a hit after hours today despite first-quarter results that beat the consensus forecast. DXCM shares were down -5.2% at $400 per share after hours. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down -0.8%. Get the full story at our sister site, Drug Delivery Business […]
Welldoc, Dexcom expand diabetes management tech partnership
Welldoc announced today that it will offer its BlueStar digital health solution with Dexcom’s G6 CGM system as a single platform. Columbia, Md.-based Welldoc’s FDA-cleared BlueStar system offers guidance to individuals through the self-management of diabetes, while Dexcom’s G6 continuous glucose monitoring (CGM) system measures glucose levels just beneath the skin’s surface and wirelessly transmits data every five […]
MedTech 100 roundup: Slight rise for the industry
While medtech’s performance still isn’t mirroring the beginning of 2021, the industry is showing signs of life with a small improvement last week. The year’s strong start, during which MassDevice‘s MedTech 100 index notched an all-time best of 110.96 points (Feb. 15) came to an end later that month and carried over into March, with the […]
How 5G could affect medtech
The latest standard of broadband technology continues to make waves in 2021. But what about medtech? Cellphone using 5G (Imagy by Frederik Lipfert on Unsplash) Wireless tech companies such as Qualcomm are predicting download speeds as high as 10 gigabits per second as next-generation 5G cellular networks roll out worldwide. The open question in medtech is […]
Dexcom promotes Jereme Sylvain to CFO
Dexcom (NASDAQ: DXCM) announced today that it has promoted Jereme Sylvain to become a new EVP and CFO at the continuous glucose monitoring company. Sylvain — who joined Dexcom in 2018 and was most recently SVP of finance and chief accounting officer — will report to COO Quentin Blackford. Previously, Blackford had been serving as […]
DTW Podcast: CEO Petrovic explains how Insulet is switching people to `Pods
Insulet CEO Shacey Petrovic says she didn’t jump immediately at the chance to join the company. In an interview with the DeviceTalks Weekly Podcast, Petrovic, who was serving as CEO of a women’s health company when CEO-Patrick Sullivan, her former boss at Cytyc, called her with an offer to serve as Insulet’s chief commercial officer […]
How CGM tech has advanced in the 21st century
The rapid evolution of the continuous glucose monitor (CGM) has brought flexibility and convenience to diabetes control. Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history. Efforts to manage glucose kicked off in earnest when researchers began measuring glucose in […]
MedTech 100 roundup: Rise to new heights continues
The medtech industry hit another high as 2021 continues to bring strong performances out of some of the biggest companies around. MassDevice‘s MedTech 100 index ended the week (Feb. 12) at 110.63 points, marking a 2.2% rise from the 108.23-point mark set at the end of the previous week (Feb. 5). The final mark for the […]
Dexcom Q4 earnings miss by a penny — but revenue up 23%
Dexcom (NSDQ:DXCM) reported mixed Q4 2020 results and reiterated a fiscal year 2021 revenue guidance that is slightly below Wall Street projections. The San Diego–based continuous glucose monitor company yesterday evening reported profits of $355.2 million, or $3.48 per share, on sales of $568.9 million for the three months ended Dec. 31, 2020, nearly quadrupling the […]
